| Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is characterized by the concomitant occurrence of often severe thrombocytopenia, microangiopathic haemolytic anaemia and a variable degree of ischaemic organ damage, particularly affecting the brain, heart and kidneys. Acute TTP was almost universally fatal until the introduction of plasma therapy, which improved survival from <10% to 80-90%. However, patients who survive an acute episode are at high risk of relapse and of long-term morbidity. A timely diagnosis is vital but challenging, as TTP shares symptoms and clinical presentation with numerous conditions, including, for example, haemolytic uraemic syndrome and other thrombotic microangiopathies. The underlying pathophysiology is a severe deficiency of the activity of a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13), the protease that cleaves von Willebrand factor (vWF) multimeric strings. Ultra-large vWF strings remain uncleaved after endothelial cell secretion and anchorage, bind to platelets and form microthrombi, leading to the clinical manifestations of TTP. Congenital TTP (Upshaw-Schulman syndrome) is the result of homozygous or compound heterozygous mutations in ADAMTS13, whereas acquired TTP is an autoimmune disorder caused by circulating anti-ADAMTS13 autoantibodies, which inhibit the enzyme or increase its clearance. Consequently, immunosuppressive drugs, such as corticosteroids and often rituximab, supplement plasma exchange therapy in patients with acquired TTP. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17020 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .
Thrombotic thrombocytopenic purpura (TTP; also known as Moschcowitz disease) is a life-threatening occlusive disorder of the microcirculation that is characterized by systemic platelet clumping, organ ischaemia (especially of the brain, heart, gastrointestinal tract and kidneys), profound thrombocytopenia (a low blood platelet count, <100 × 10 9 cells per litre, often <30 × 10 9 cells per litre) and fragmentation of red blood cells. The disease was first described by Eli Moschcowitz in 1924 (REF. 1); however, its cause remained enigmatic until Moake et al. 2 reported four patients with chronic relapsing TTP who lacked the capacity to process von Willebrand factor (vWF). Subsequently, other investigators demonstrated that this inability to cleave vWF was the result of a severe deficiency of a metalloproteinase [3] [4] [5] , which was later characterized as a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13; FIG. 1) and identified as the protein with vWF-processing activity that was defective or lacking in TTP [6] [7] [8] [9] [10] . Thus, TTP is defined as thrombotic microangiopathy (TMA) with severe deficiency of ADAMTS13 activity.
Severe ADAMTS13 deficiency (<10% of the normal enzyme activity) is the result of either homozygous or compound heterozygous mutations in ADAMTS13 (REFS 9, (11) (12) (13) (14) (15) (hereditary or congenital TTP (cTTP); also known as Upshaw-Schulman syndrome 16, 17 (Online Mendelian Inheritance in Man (OMIM) #274150)), or of anti-ADAMTS13 autoantibodies in acquired, immune-mediated TTP (iTTP) [3] [4] [5] 18 , which is the more prevalent form. TTP is a chronic condition that can manifest as acute episodes of TMA.
Although a rare disease, TTP is the focus of much investigation by clinicians and researchers because of its complex pathophysiology, the still high mortality of acute episodes (up to 20%) and the continuing risk of relapse in survivors of a first acute disease episode 19 . In this Primer, we discuss the molecular and clinical aspects of TTP, as well as future research directions. We also distinguish TTP from other TMAs that have similar clinical presentations but often a distinct pathophysiology.
Epidemiology iTTP iTTP mainly affects adults, with peak incidences in the third to fifth decades of life in Europe and the United States 20-23 , and in the seventh decade of life in Japan 24 . Similarly to other autoimmune diseases, black (African Americans or African Caribbeans) individuals and women are more frequently affected than non-black individuals and men, with female to male ratios ranging from 2.5:1 to 3.5:1 in different cohorts 21, 22 . Of note, in the Japanese cohort, men and women ≥60 years of age were equally affected 24 . iTTP is very rare in individuals <18 years of age, with considerable numbers only reported among Japanese 24 and Polynesian populations 25 , who possibly share a common ethnic origin in South East Asia.
The annual incidence of clinically diagnosed, idiopathic TMA (irrespective of ADAMTS13 activity) was estimated at between 3.7 and 4.43 cases per million 20, 26 and the incidence of iTTP was estimated to be 2.17 cases per million (95% CI: 2-2.34) 22 . Point prevalence estimates of adult-onset iTTP and its proportion among all forms of TMA were reported for France (13 cases per million and 24%, respectively), and calculated for Oklahoma (18 cases per million and 23%) and Japan (3 cases per million and 21%) 23 .
Additional autoimmune manifestations or even disorders are frequently observed in patients with iTTP 19, 24, 27, 28 . In particular, patients with iTTP and also underlying connective tissue diseases, especially systemic lupus erythematosus, are considered a special entity and often show severe ADAMTS13 deficiency in the presence of non-inhibitory anti-ADAMTS13 autoantibodies 29, 30 .
Besides ethnicity, evidence exists for a certain genetic predisposition to develop pathogenic anti-ADAMTS13 autoantibodies. In white individuals, the HLA-DRB1*11 allele of the major histocompatibility complex (MHC) class II gene family was found to be over-represented in patients with iTTP, whereas HLA-DRB1*04 was more prevalent among healthy controls, suggesting a protective effect of this allele [31] [32] [33] . The overall lower prevalence of HLA-DRB1*04 in black individuals might contribute to their higher susceptibility to develop iTTP 34 . However, familial occurrence of iTTP has been reported in two families, even though none of the patients carried the HLA-DRB1*11 allele 35, 36 , pointing to other yet unidentified genetic risk factors. Finally, among patients diagnosed with acute iTTP, carriers of heterozygous ADAMTS13 mutations have been observed [37] [38] [39] . Of seven patients with iTTP who carried heterozygous ADAMTS13 mutations, six had anti-ADAMTS13 IgG autoantibodies that were functional inhibitors and one had non-inhibitory anti-ADAMTS13 autoantibodies. Given the overall low prevalence of ADAMTS13 mutations (see below), the number of heterozygous ADAMTS13 mutation carriers among patients diagnosed with iTTP is remarkable and hints at a role of ADAMTS13 sequence variants in trigger ing the development of anti-ADAMTS13 autoantibodies or in expediting a drop in ADAMTS13 activity below a critical threshold to set off an acute iTTP episode. Of note, obligatory heterozygous ADAMTS13 mutation carriers, such as parents of patients with cTTP, typically have an ADAMTS13 activity of about 50% and are generally healthy, although mild thrombocytopenia during pregnancy or infections has been reported in some of them 40, 41 .
cTTP
In cTTP, severe ADAMTS13 deficiency is the result of compound heterozygous or homozygous mutations in ADAMTS13. More than 100 different causative ADAMTS13 mutations have been identified, including missense (~62%), nonsense (~12.5%), splice site (~8%) and frameshift (deletions or insertions; ~17.5%) mutations, spreading over all ADAMTS13 protein-coding domains 9, [11] [12] [13] [14] [15] [42] [43] [44] [45] [46] [47] . As is typical of autosomal recessive disorders, individuals carrying homozygous ADAMTS13 mutations are primarily found in families with documented parental consanguinity, with the exception of two recurring ADAMTS13 mutations: the frameshift mutation c.4143_4144dupA in exon 29 and the missense mutation c.3178C>T (p.R1060W) in exon 24 (REFS 12, 38, 42, (46) (47) (48) . Whereas c.4143_4144dupA has been described in families originating from central and northern Europe and accounted for many cases of cTTP among unrelated individuals in Scandinavia and around the Baltic Sea 42, 46 , the distribution of p.R1060W is even more widespread. It is the predominant mutation in British and French patients, but has also been reported in families with a history of cTTP from Scandinavia, central Europe, Italy and Turkey, as well as in North Americans of European descent 38, 47 .
cTTP affects men and women equally. Although the prevalence of cTTP is unknown, it has been postulated that it accounts for <5% of all acute cases of TTP 23, 49 . A population screening in healthy Japanese adults, stratified according to levels of ADAMTS13 activity, identified a substantial number of carriers of heterozygous ADAMTS13 mutations, and the authors speculated that the actual prevalence of cTTP could be up to threefold higher than the estimate based on diagnosed patients (~0.4 cases per million) 50 . The point prevalence of cTTP in central Norway was 16.7 cases per million 46 . This number was mirrored by an allelic frequency of the two most prevalent ADAMTS13 mutations in this population, c.4143_4144dupA and c.3178 C>T (p.R1060W) of 0.04-0.33% and 0.3-1%, respectively. A slightly lower allelic frequency (0.06%) for the p.R1060W mutation was documented in the Rotterdam study, a population-based cohort study in the Netherlands 51 . In all population screen ings carried out to date, only heterozygous mutation carriers have been identified.
Age at diagnosis in cTTP shows a bimodal distribution, with about half of patients presenting with their first episode of TTP by 2-5 years of age, and a second peak in early adulthood, with the inaugural episode specifically frequent during pregnancy 41, 43, 52, 53 . Indeed, among women who had an episode of TTP during their first pregnancy, the frequency of cTTP was 25-66% 44, 45 . In this subgroup of women with cTTP, the prevalence of p.R1060W is remarkable: in the UK and French cTTP cohorts, 17 out of 23 (74%) and 16 out of 21 (76%) patients, respectively, were either compound heterozygous or homozygous carriers of this mutation 23, 45 . Of note, patients with cTTP heterozygous for p.R1060W have regularly measurable residual ADAMTS13 activity of 3-6% of the physiological levels; homozygous p.R1060W carriers even have 5-12% 53, 54 . This observation suggests that, unlike most cTTP-associated mutations, which result in no residual ADAMTS13 activity, p.R1060W causes a less severe loss of enzymatic function. The level of residual ADAMTS13 activity was suggested to be an important determinant of clinical severity with early onset (<18 years of age), the need for prophylactic plasma therapy and an annual event rate of >1 associated with ADAMTS13 activity of <3% 53, 55 . However, the variable disease course in patients with a homozygous c.4143_4144dupA mutation (who typically have ADAMTS13 activity of <1%) suggests that there have to be additional determinants of clinical severity in cTTP 42, 46 .
Mechanisms/pathophysiology ADAMTS13 ADAMTS13 is mainly synthesized in the liver by hepatic stellate cells [8] [9] [10] 56, 57 . In addition, renal podocytes and tubular epithelial cells 48, 58 , platelets 59 and endothelial cells 60 synthesize biologically active ADAMTS13. After folding in the endoplasmic reticulum, ADAMTS13 is active and is released as an active enzyme into the circulation 61 .
Apoptosis of hepatic stellate cells in rats or partial hepatectomy in rats and in humans led to a marked reduction in plasma ADAMTS13 activity to 30-40% [62] [63] [64] , which suggests that ADAMTS13 expression in other tissues contributes to normal plasma levels of around 1 μg per ml (REF. 6) . The enzyme has a long plasma halflife of 2-3 days 65 and about 3-5% of ADAMTS13 circulates bound to soluble vWF 66 . There is no physiological inhibitor of ADAMTS13 activity, and as of today, information on pathways that are involved in ADAMTS13 clearance is lacking.
Processing of vWF
The only known substrate for ADAMTS13 is vWF, a multimeric plasma glycoprotein that is exclusively synthesized by endothelial cells and megakaryocytes 67 (FIG. 2) . vWF biosynthesis is complex and involves the removal of the signal peptide and propeptide, glycosylation, sulfation, dimerization and, finally, multimerization 68, 69 . Synthesized vWF multimers are either constitutively released from the endothelial cells or, more importantly, stored as ultra-large vWF multimers, Figure 1 | Structure of ADAMTS13. ADAMTS13 (which encodes a disintegrin and metalloproteinase with thrombospondin motifs 13, a metalloproteinase of 1,427 amino acids with a multidomain structure) is located on chromosome 9q34, covers about 37 kb (REF. 9) and neighbours the ABO blood group locus. The calculated molecular weight of ADAMTS13 is 145 kDa, and plasma-purified ADAMTS13 has an apparent molecular weight of 180-190 kDa owing to glycosylation of about 20% of its mass. The schematic representation of the domain structure of ADAMTS13 shows: a signal peptide (SP), a propeptide (P), a metalloproteinase domain (M), a disintegrin-like domain (D), a first thrombospondin type 1 repeat (T1), a cysteine-rich domain (C), a spacer domain (S), seven thrombospondin type 1 repeats (T2-T8) and two CUB domains (CUB1 and CUB2) that are highly homologous to domains found in the complement receptor complex, complement C1r subcomponentcomplement C1s subcomponent (C1r-C1s), the embryonic sea urchin epidermal growth factor and bone morphogenetic protein 1. Almost all patients with acquired, immune-mediated thrombotic thrombocytopenic purpura (iTTP) have anti-ADAMTS13 autoantibodies with an epitope in the spacer domain (antibody in green), although in many patients, anti-ADAMTS13 autoantibodies with epitopes in other ADAMTS13 domains are also present. In patients with hereditary TTP, mutations in ADAMTS13 (*) are spread over the different protease domains. Left inset: crystal structure of the DTCS domains with a modelled structure of the M domain. Five amino acid residues (shown in blue) -Arg568, Phe592, Arg660, Tyr661 and Tyr665 -constitute an antigenic surface that is recognized by the majority of the inhibitory anti-ADAMTS13 autoantibodies. The active site is indicated by a red arrow. Right inset: molecular model of ADAMTS13 as determined by small angle X-ray scattering. Left inset adapted with permission from REF. 223 D  T1  C  S  T2  T3  T4  T5  T6  T7  T8 CUB1 CUB2
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Antibody together with an equimolar amount of vWF propeptide, in Weibel-Palade bodies (storage granules) in endothelial cells or in α-granules of megakaryocytes and platelets 68, 69 . Upon stimulation by various agonists, such as cytokines (for example, tumour necrosis factor or IL-8) and histamine, or by fluid shear stress, ultra-large vWF multimers are rapidly secreted from endothelial cells and can remain anchored to the endothelial surface as long, string-like, hyper-adhesive structures or can be released into the circulation. The shear conditions of the blood flow unfold both anchored and freshly released ultra-large vWF multimers 70, 71 , thereby exposing otherwise cryptic platelet-binding sites and the ADAMTS13 cleavage site (FIG. 2b) . ADAMTS13 activity is regulated by conformational changes in its substrate, in a so-called molecular zipper mechanism 72 . Conformational activation was shown to also occur in ADAMTS13 , which circulates in a closed conformation with its CUB domains interacting with the spacer domain 73 (FIG. 1) . Binding of vWF to this closed ADAMTS13 conformation leads to the exposure of functional exosites (secondary binding sites) in the ADAMTS13 spacer domain and, hence, conformational activation of the protease 73, 74 . This process possibly optimizes vWF cleavage under fluid shear stress in vivo but might also make ADAMTS13 suscep tible to immune recognition 73, 74 . Proteolysis of ultra-large vWF multimers generates shorter multi mers of vari able molecular weight, depending on where ADAMTS13 cleavage takes place. The resulting smaller multimers again adopt a folded conformation, which prevents spontaneous binding of platelets and further digestion by ADAMTS13 (REF. 72 ).
TTP pathogenesis
When ADAMTS13 activity is lacking, ultra-large vWF multimers persist in the circulation (FIG. 3) , and the spontaneous binding of platelets is no longer restrained. Thus, the ultra-large vWF multimers bind to, accumulate and activate platelets, forming the vWF-rich microthrombi that are a hallmark of TTP (FIG. 3b) . These disseminated microthrombi scavenge platelets, which causes thrombo cytopenia, mechanically destroy red blood cells, which leads to haemolytic anaemia with fragmented red blood cells (schistocytes) that are visible on the peripheral blood smear, occlude the microcirculation and cause organ ischaemia.
Anti-ADAMTS13 autoantibodies
iTTP is characterized by the appearance of inhibitory or non-inhibitory autoantibodies against ADAMTS13. In the majority of patients, strong functional ADAMTS13 inhibitors can be demonstrated by Bethesda-like assays (see below) 4, 5, 76 . However, 10-25% of patients have non-inhibitory anti-ADAMTS13 autoantibodies, which have been postulated to acceler ate ADAMTS13 clearance [77] [78] [79] . As the plasma levels of ADAMTS13 antigen are also severely reduced in the majority of patients with , three A domains (A1, A2 and A3), six C domains (C1-C6) and one cystine knot (CK) domain. The vWF A1 domain harbours the platelet glycoprotein Ib (GPIb) and a collagen-binding site, the vWF A2 domain contains the a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) cleavage site, the vWF A3 domain has another collagenbinding site and the vWF C4 domain contains the platelet integrin αIIbβ3-binding site 69, 224 . The CK domain is involved in tail-to-tail dimerization and the DʹD3 domain in head-to-head multimerization of vWF dimers. Drawings represent the conformation of two propeptides and a vWF dimer. b | Domain structure of vWF with highlighted crystal structure of the folded A2 domain with hidden ADAMTS13 cleavage site (upper panel) and a model of the unfolded A2 domain with an accessible ADAMTS13 cleavage site, which occurs after shear-induced unfolding of vWF (lower panel). First, ADAMTS13 binds through its thrombospondin type 1 repeats T5-CUB domains to the D4-CK domains of folded vWF 66, 225 . Next, shear forces expose cryptic vWF A2 domain exosites, which interact with the ADAMTS13 spacer domain 72 , followed by the ADAMTS13 disintegrin-like domain and the metalloproteinase domain, which finally proteolyses the Tyr1605-Met1606 scissile bond in the vWF A2 domain 226 . Part b adapted with permission from REF. 223 , National Academy of Sciences. C1  C2  C3  C4  C5  C6  CK  C1  C2  C3  C4  C5  C6  CK   C1  C2  C3  C4  C5  C6  CK   D3  D2 D′  A1  A2  A3  D4  D3  D′  A1  A2  A3  D4   D3  D′  A1  A2  A3 
iTTP, clearance of the enzyme is probably an important contributing mechanism to the reduced protease activity, besides the direct inhibition by autoantibodies [78] [79] [80] .
Autoantibodies that recognize the spacer domain of ADAMTS13 are present in 97-100% of patients with iTTP 79, [81] [82] [83] , and virtually all inhibitory anti-ADAMTS13 autoantibodies that are identified by routine assays are directed to the ADAMTS13 spacer domain 79 . Epitope fine mapping showed that five amino acid residues (FIG. 1) constituted the principal antigenic surface for the majority of inhibitory anti-ADAMTS13 autoantibodies [84] [85] [86] [87] [88] . However, the autoimmune response against ADAMTS13 is polyclonal, and about two-thirds of patients also have antibodies against other ADAMTS13 domains 79,81-83 , although these epitopes have not been fine mapped.
Non-inhibitory anti-ADAMTS13 autoantibodies have also been observed in 4-15% of healthy controls and blood donors, as well as in numerous patients with cTTP, in whom titres were often fluctuating. In some of these patients with cTTP, the treatment interval of regular plasma prophylaxis to supplement ADAMTS13 levels had to be shortened based on clinical judgement (mainly because of the development of neurocognitive symptoms), despite full recovery and a normal plasma half-life of infused exogenous plasma ADAMTS13 (REFS 40, 43) . So far, functional ADAMTS13 inhibitors have been described in only two patients with cTTP 43, 89 . These inhibitors were not boosted by subsequent plasma therapy, and are thus reminiscent of low-titre inhibitors in haemophilia A.
Anti-ADAMTS13 autoantibodies are predominantly of the IgG class, but also IgM and IgA have been reported in a limited number of patients with iTTP 29,90,91 . Among the anti-ADAMTS13 IgG autoantibodies, the IgG4 subclass prevails, followed by IgG1, IgG2 and IgG3 (REFS 86, 91) . High IgG4 titres were shown to be associated with an increased risk of relapse, and IgG4 was often the only anti-ADAMTS13 isotype. In a small number of patients, the presence of IgA or IgG1, or both, at presentation with an acute TTP episode was associated with adverse outcome 90, 91 .
Anti-ADAMTS13 autoantibodies frequently use VH1-69 and VH1-3 in the variable segment of the heavy-chain locus 88, 92 , and somatic mutation rates of characterized anti-ADAMTS13 autoantibodies suggest affinity maturation 88, 92, 93 . In longitudinal studies over multiple relapses, functional maturation (that is, from non-inhibitory to inhibitory anti-ADAMTS13 autoantibodies) or epitope spreading (the development of an immune response to additional ADAMTS13 epitopes), or both, was demonstrated in some patients, suggesting a continuous shaping of the autoimmune response to ADAMTS13 in iTTP 79, 94 .
The unexpectedly high ADAMTS13 antigen plasma levels in some samples of patients with iTTP, despite the presence of anti-ADAMTS13 autoantibodies, prompted the detection of circulating ADAMTS13 immune complexes 78 , which are formed by the integral binding of ADAMTS13 to an anti-ADAMTS13 autoantibody. These enzymatically inactive immune complexes were subsequently found not only during acute episodes and relapses [94] [95] [96] [97] but also in patients in clinical remission, even years after the last acute TTP episode 96 . Moreover, the presence of ADAMTS13 immune complexes seemed to be predictive of a higher probability of recurrence of acute TTP events in the first 2 years after disease onset 97 .
The mechanisms involved in the loss of tolerance to ADAMTS13 remain unknown. The formation and maturation of antibodies requires immune recognition, endocytosis and processing of ADAMTS13 into peptides that are presented on MHC class II molecules of antigenpresenting cells. Sugar moieties on ADAMTS13 can interact with mannose receptors on antigen-presenting cells, thereby promoting endocytosis of the protease 98 . Studies have shown that peptides derived from the CUB2 domain of ADAMTS13 were presented by MHC class II molecules encoded by HLA-DRB1*11 and HLA-DRB1*03 and that patients with iTTP had circulating CD4 + T cells in peripheral blood that were reactive to peptides derived from the CUB2 domain 99, 100 .
Diagnosis, screening and prevention
Clinical presentation TTP often presents with an acute onset and severe disease course 101 . Amorosi and Ultmann 102 reviewed 271 patients from the literature and delineated the diagnostic pentad of clinical findings that were present in 88-98% of patients (however, owing to early diagnosis, the complete pentad is now rarely present in patients diagnosed with acute TTP 101,103-106 ). These signs are fever, purpura or haemorrhage associated with thrombocytopenia, haemolytic anaemia with schistocytes on the blood smear, neurological manifestations (which are often transient, ranging from headache or mental changes to focal signs, seizures and coma) and variable degrees of renal dysfunction. Haemolytic uraemic syndrome (HUS), which is a TMA that predominantly affects the kidneys, was recognized as one of the possible differential diagnoses 107 .
Although the onset of disease is typically sudden, prodromal manifestations (including fatigue, arthralgia, myalgia and abdominal or lumbar pain) that suggest a flu-like episode are frequently reported at the time of diagnosis or during the preceding days. Cardiac events may include non-ST-elevation myocardial infarction (non-STEMI) and STEMI, congestive heart failure, arrhythmias, cardiogenic shock and sudden cardiac arrest. An increased serum cardiac troponin level upon presentation was an accurate predictor of subsequent acute myocardial infarction, as well as death and treatment refractoriness 108, 109 . Digestive tract involvement, including abdominal pain, nausea, vomiting and diarrhoea, was reported in up to one-fourth of cases. Autopsy studies revealed that microvascular thrombi are present in almost all organs: particularly in the brain (primarily in the cerebral cortex), heart, kidneys and the digestive tract, but also in the spleen, pancreas and adrenal glands. In the absence of adequate management, patients develop multiple organ failure and eventually die within days or weeks.
Differential diagnosis of TTP
The clinical signs, even when all symptoms of the classic pentad are simultaneously present, are not specific for TTP, and a series of other TMAs and disorders that result in similar manifestations have to be considered. Because TTP is a medical emergency, a rapid diagnosis is essential. Assessment of ADAMTS13 activity is pivotal in evaluating a patient who presents with an acute TMA. However, the results of ADAMTS13 activity assays are not always readily available, and because of high mortality rates, treatment cannot be postponed. Thus, a presumptive diagnosis has to be made and treatment initiated based on clinical presentation, the presence or absence of certain conditions or comorbidities and routine laboratory tests (FIG. 4) . Although the leading signs might guide the clinician in formulating Proteolysis by a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) of ultra-large von Willebrand factor (vWF) multimeric strings that are anchored to or secreted from stimulated microvascular endothelial cells. ADAMTS13 cleaves the A2 domain of a vWF monomeric subunit at Tyr1605-Met1606 to prevent and regulate platelet adherence (via glycoprotein Ib) to the A1 domain. b | A microvessel in thrombotic thrombocytopenic purpura (TTP). When ADAMTS13 activity is <10% of normal level, cleavage of secreted or anchored ultra-large vWF strings is severely reduced. The results are: excessive microthrombi formation, shear injury to red blood cells flowing through microvessels that are partially occluded by platelet clumps (producing schistocytes and haemolysis) and activation of the alternative complement pathway on the uncleaved ultra-large vWF strings (inset). Activated complement factors C3 (C3b) and B (Bb) attach to a string in complexes of C3b-Bb (C3 convertase) and C3b-Bb-C3b (C5 convertase). C3a and C5a are anaphylatoxins that are liberated by proteolytic cleavage of C3 and C5, respectively. Other components that bind to uncleaved ultra-large vWF strings are: complement factor D (not shown), which cleaves and activates factor B; complement factor P (properdin), which stabilizes C3 convertase and C5 convertase; and complement factor H and factor I (not shown), which are the negative regulators of C3 convertase. However, the binding of factor H and factor I is insufficient to block C3 convertase activity generated on the strings. c | Plasma vWF. Sodium dodecyl sulfate (SDS)-agarose gel electrophoresis of plasma from a healthy individual (control) and a patient with congenital TTP (cTTP) in remission highlights high-molecular-weight (HMW) vWF multimers and ultra-large (UL) vWF multimers. Of note, ultra-large vWF multimers are less likely to be seen during relapse, perhaps because these hyperadhesive forms adhere to and aggregate platelets in the microcirculation. MAC, membrane attack complex. a diagnosis, it should be kept in mind that none of the routine biomarkers, such as creatinine and lactate dehydro genase levels and platelet counts, is specific for or can formally rule out one condition.
Shiga toxin-associated HUS. A differential diagnosis of TTP is Shiga toxin (STX)-associated HUS (also known as typical HUS), caused by STX-producing, enterohaemorrhagic bacteria, mainly Escherichia coli. STX-HUS mostly occurs in children <5 years of age and is rarely seen in adults 110 . Following a prodromal phase of diarrhoea, which turns bloody after 1-2 days, patients present 5-7 days later with a clinical triad of thrombocytopenia, microangiopathic haemolytic anaemia and often severe renal insufficiency. These patients have generally normal or only mildly reduced ADAMTS13 activity 111, 112 . However, surprisingly, 1 out of 29 children with STX-HUS in a study by Hunt et al. 111 had an acquired severe ADAMTS13 deficiency that had resolved when tested 3 years later. Furthermore, 21 of 322 adult patients from the Oklahoma TTP-HUS registry presented with bloody diarrhoea, and E. coli O157:H7 was identified in some of them, although not all patients were systematically tested 113 . Two of 16 patients of this study who were tested had a severe ADAMTS13 deficiency 113 . Finally, during the German E. coli O104:H4 outbreak in 2011, two out of six severely affected patients investigated showed a severe autoantibody-mediated ADAMTS13 deficiency 114 , suggesting a final diagnosis of iTTP, possibly triggered by enterohaemorrhagic E. coli infection. Altogether these observations suggest that severe enterohaemorrhagic E. coli infection might lead not only to STX-HUS but, in rare cases, also to an autoimmune response against ADAMTS13, or that STX could trigger acute TMA in a few patients with a pre-existing autoimmune response against ADAMTS13. Of note, STX can bind to a restricted region between the vWF A1 and A2 domains, thereby reducing the rate of vWF proteolysis by ADAMTS13 (REF. 115 ).
Atypical HUS. Another differential diagnosis of TTP that must be considered, especially when renal insufficiency is prominent, is atypical HUS (aHUS), which is often linked to uncontrolled activation of the alternative pathway of the complement system. Various mechanisms can underlie this excessive activation: gain-of-function mutations in C3 and CFB (the genes encoding the complement factor C3 and complement factor B, respectively); defective complement regulation due to mutations in CFH, CFI, CD46 (also known as MCP) or THBD, which encode complement factor H (CFH), complement factor I (CFI), membrane cofactor protein (MCP) and thrombomodulin, respectively; or autoantibodies against CFH. CFH mutations are the most prevalent, accounting for ~25% of identified mutations in individuals with aHUS, followed by mutations in CD46 and CFI 116, 117 . aHUS is rare: it is estimated to account for <5% of all HUS cases, and penetrance varies depending on the underlying mutation. Besides familial occurrence, sporadic cases have been reported 116, 117 .
Drug-associated TMA. Several drugs, such as calcineurin inhibitors, antineoplastic agents (that is, mitomycin C or gemcitabine), inhibitors of vascular endothelial growth factor, quinine or intravenous abuse of oral oxymorphone, have been implicated in the induction of acute TMA, usually with no associated ADAMTS13 deficiency. An exception is ticlopidine, an antiplatelet drug of the thienopyridine family, which has rather frequently led to acute TTP after 2-4 weeks of intake; in all instances investigated, a severe autoantibody-induced ADAMTS13 deficiency was found 118, 119 . The newer thienopyridines, clopidogrel and prasugrel, which have replaced ticlopidine for safety reasons, rarely induce TMA. ADAMTS13 activity was usually normal and anti-ADAMTS13 inhibitory auto antibodies were usually absent in individuals who developed TMA as a consequence of clopidogrel treatment 120, 121 .
TMA associated with haematopoietic stem cell transplantation or disseminated neoplasia. TMA associated with haematopoietic stem cell transplantation is almost never accompanied by severe ADAMTS13 deficiency 19,122-124 . However, endothelial cell toxicity caused by either preceding chemotherapy or irradiation, or a graft-versus-host reaction to host endothelial cells 125 might have a pathophysiological role. Similarly, TMA associated with disseminated neoplasia, often presenting with a pronounced leukoerythroblastic haemogram that is indicative of bone marrow metastasis, is seldom accompanied by severe ADAMTS13 deficiency 19, [122] [123] [124] .
HIV infection. The percentage of patients with acute TMA who also have HIV infection varies consider ably in different case series, from 0 out of 48 patients (0%) to 20 out of 24 patients (83%), and depends on the geographical location and hence the prevalence of HIV infection, as well as the availability of health care and highly active antiretroviral therapy 126 . In South Africa, HIV infection is by far the most common cause of TMA 127 , whereas in Europe, before antiretroviral therapy became available, 1-2% of patients with HIV infection developed a TMA, which, after the intro duction of antiretroviral therapy, is now hardly seen 128 . In a prospective registry from France, 29 out of 236 patients with acute TMA also had HIV infection 129 . Of these patients, 17 out of 29 had an ADAMTS13 activity of <5% and had fewer AIDS-related complications and higher CD4 + T cell counts than the 12 patients with an ADAMTS13 activity of >5%. The prognosis was better in those with severe autoimmune ADAMTS13 deficiency 129 , who probably had iTTP secondary to HIV infection. The other 12 patients with an ADAMTS13 activity of >5% had another form of TMA, which was possibly related to infectious complications. Of special interest is one patient infected with HIV from the Oklahoma TTP-HUS registry who had recurring classic TMA bouts with documented anti-ADAMTS13 autoantibodies from the first presentation but severe ADAMTS13 deficiency only in later acute episodes 94, 126 , indicative of antibody shaping or maturation over time.
Connective tissue disorders. TMA can occur in individuals affected by connective tissue disorders, including systemic lupus erythematosus, rheumatoid arthritis and systemic sclerosis. A large study from Japan that included 127 patients with TMA associated with connective tissue disorders showed that the majority of these patients had normal or mildly to moderately decreased ADAMTS13 activity, although some patients with systemic lupus erythematosus or rheumatoid arthritis had a severe autoantibody-mediated ADAMTS13 deficiency and, therefore, iTTP secondary to connective tissue disorders 30 . Thus, iTTP secondary to systemic lupus erythematosus is possible.
Pregnancy-induced TMA. Correctly diagnosing pregnant women who present with an acute TMA is challenging, as pregnancy has been associated with a wide range of TMAs 44, 105, 130 . Pre-eclampsia and HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome show features that are difficult to distinguish from classic TTP. Arterial hypertension and oedema in pre-eclampsia and severe liver damage in HELLP syndrome are differential diagnostic clues. Both pre-eclampsia and HELLP syndrome usually manifest in the third trimester, typically after the 34th gestational week and promptly resolve within days after delivery 103 . In HELLP syndrome, ADAMTS13 activity is normal or mildly reduced, but the vWF A1 domain might be more often in a glycoprotein Ib-binding conformation 131 . cTTP is much less common than HELLP, but might first manifest during pregnancy 44, 52, 130, 132 . Virtually every woman with cTTP will have an acute episode of TTP during her first pregnancy, often before the third trimester, even if she had been asymptomatic until then. iTTP can also manifest during pregnancy 44 . However, whereas women with cTTP will almost invariably show a disease flare-up during an ensuing pregnancy, women with iTTP who experience an episode during their first pregnancy seem to have a moderate risk of relapse but an increased risk of pre-eclampsia in a consecutive pregnancy 133 .
ADAMTS13 assays and interpretation
The status of ADAMTS13 in a patient can be assessed in various ways. Activity assays measure the ability of the enzyme to cleave vWF multimers or vWF peptides, antibody assays determine the presence of anti-ADAMTS13 autoantibodies and/or their inhibitory potential, and antigen assays measure the plasma concentration of the protease (TABLE 1) . ADAMTS13 activity assays using multimeric vWF substrate used to be difficult to perform and laborious. In 2004, Kokame et al. 134 found that the minimal functional substrate for ADAMTS13 comprised 73 amino acid residues (D1596 to R1668) in the vWF A2 domain and developed a fluorescence resonance energy transfer (FRET)-based assay 135 . This FRETS-VWF73 assay and other similar assays 136 have become widely available in diagnostic laboratories, show very good reproducibility and are now pushing towards detection limits below 5% [135] [136] [137] [138] [139] . The presence and levels of functional ADAMTS13 inhibitory autoantibodies are assessed in a Bethesda-like assay by mixing a sample of heat-inactivated plasma from the patient with a plasma pool from healthy controls and measuring the residual ADAMTS13 activity in the mixture. The inhibitory autoantibodies in the plasma of the patient neutralize ADAMTS13 that is present in the control sample. One inhibitor unit (Bethesda unit per ml) is defined as the amount of autoantibodies that reduces ADAMTS13 activity in control plasma to 50% 140 . The total plasma level of anti-ADAMTS13 IgG antibodies (whether inhibitory or non-inhibitory) can be assessed by various custom-made or commercially available enzyme-linked immunosorbent assays (ELISAs), using ADAMTS13 as immobilized antigen. In addition, the plasma levels of ADAMTS13 antigen can be assessed by ELISA, but the levels of ADAMTS13 antigen are not considered relevant for diagnosis or for guiding treatment in TTP.
There are limitations to each of these tests. In the FRETS-VWF73 assay, free haemoglobin or bilirubin in the plasma of patients who are hyperbilirubinaemic, which may occur in TTP as a result of haemolysis, act as fluorescence quenchers, resulting in inaccurately low ADAMTS13 activity 141 . In the absence of protease inhibitors, such as Pefabloc SC (Sigma-Aldrich), other proteases that are present in plasma samples might interfere with accurate measurement of ADAMTS13 activity 136 . In particular, leukocyte-derived proteases cleave near or at the scissile bond in the vWF A2 domain, which may theoretically lead to overestimating ADAMTS13 activity 142 . In patients with iTTP, extensive plasma dilution required for some assays might lead to the dissociation of ADAMTS13 immune complexes, resulting in overestimation of ADAMTS13 activity 94 . An improved assay using undiluted plasma samples has been reported 143 . ADAMTS13 inhibitor levels assessed by static assays are not always consistent with those obtained by assays performed under flowing fluid conditions, possibly because certain ADAMTS13 epitopes are selectively exposed under shear 144 or because ADAMTS13 inhibitory autoantibodies that target an epitope in the ADAMTS13 carboxy-terminal domains are not identified by vWF peptide-based activity assays. A negative result of a Bethesda-like assay or an antibody ELISA should be controlled in a second sample.
Distinction between iTTP and cTTP
Distinction between iTTP and cTTP is mandatory to help guide treatment and follow-up. In cTTP, the functional ADAMTS13 inhibitory autoantibody test is negative, severely reduced ADAMTS13 activity persists over time and a full recovery of ADAMTS13 activity is expected upon plasma infusion with a plasma halflife of infused ADAMTS13 of 2-3 days (REFS 65, 145) . Molecular analysis to determine the presence of causative ADAMTS13 mutations can help to distinguish between cTTP and iTTP.
Management
Acute TTP episodes are medical emergencies: maximal resuscitative measures might be required and the immedi ate outcome might not be predictable. In several centres, patients are routinely treated in intensive care units during the first few days. Older age, an increased plasma level of cardiac troponin, which indicates damage to the myocardium, and very high levels of lactate dehydro genase at diagnosis were associated with increased mortality and treatment refractoriness 108, 109, 146 .
Plasma therapy
Plasma therapy is used to manage both iTTP and cTTP. There are two kinds of plasma therapy: plasma infusions and therapeutic plasma exchange (TPE). TPE with replacement of fresh frozen or solvent detergent plasma remains the cornerstone of current management of iTTP. By replacing large volumes of the plasma of the patient, TPE replenishes the activity of ADAMTS13 and removes anti-ADAMTS13 autoantibodies, ADAMTS13 immune complexes, high-molecular-weight vWF multimers and inflammatory cytokines, although this removal has not been formally demonstrated. The introduction of TPE in the early 1980s led to an impressive improvement in the prognosis of TTP, with survival rates rising from <10% to >80% 147 . In 1991, a randomized controlled trial of plasma infusion versus TPE for the treatment of adult patients with TTP established a plasma volumedependent response rate (defined as a platelet count of >150 × 10 9 cells per litre and no new neurological events) by day 9 of 47% for TPE versus 27% for plasma infusion, and survival at 6 months of 78% versus 49%, respectively) 148 . TPE is performed daily until the platelet count has stably recovered, haemolysis has ceased and no additional organ dysfunction occurs. TPE initially usually requires the exchange of 1.5 times the patient's plasma volume, then the volume can be reduced to 1 times the patient's plasma volume after a few days. A twice-daily TPE treatment in severe, initially refractory iTTP has been reported 149, 150 , but the benefit of this regimen was difficult to assess as other treatments were often initiated or intensified simultaneously. In cTTP, plasma infusions are usually sufficient, although, sometimes, a few TPE sessions might be required to treat acute episodes [43] [44] [45] 132 . Regular plasma infusions are effective in preventing acute episodes in cTTP, but there are no official guidelines indicating when a prophylactic plasma regimen should be started.
Corticosteroids
Given the autoimmune nature of iTTP, there is a rationale for the use of corticosteroids, although there are few randomized controlled trials. Before the systematic use of TPE was introduced, it was reported that 30 out of 54 (55%) patients with TTP without consider able organ involvement responded within 48-72 hours to corticosteroids alone 151 . A randomized controlled trial compared standard-dose with high-dose methylprednisolone as an adjunctive therapy to TPE in 60 patients with newly diagnosed iTTP 152 . After 23 days of treatment, remission was achieved in 77% and 47% of patients in the high-dose and standard-dose arms, respectively. Following the introduction of corticosteroids as routine adjunctive treatment to TPE in the Oklahoma TTP-HUS registry, the reported number of TPE sessions required to achieve remission was reduced, a finding that was paralleled by a reduction of treatment-associated complications 153 . Altogether, these data indicate that corticosteroids in association with TPE are beneficial in the management of iTTP.
Biologic therapy
Rituximab, a humanized anti-CD20 monoclonal antibody that was originally developed to treat CD20 + B cell neoplasia, was first introduced as iTTP treatment in patients who had a suboptimal response (that is, disease exacerbation, defined as a recurrence of thrombocytopenia during the period of daily TPE or within 30 days of stopping TPE, or refractoriness) to conventional therapy, with the aim of suppressing the production of anti-ADAMTS13 autoantibodies [154] [155] [156] [157] [158] [159] [160] . In these patients, daily TPE was usually continued and rituximab was administered periodically after a TPE session, most often weekly for 4 weeks (TABLE 2) . Rituximab was associated with a rapid and substantial depletion of peripheral B cells, more-frequent recovery of ADAMTS13 activity and more-effective depletion of anti-ADAMTS13 autoantibodies. In addition, two prospective studies reported on patients treated with rituximab as front-line therapy 158, 161 , which resulted in fewer and delayed relapses [158] [159] [160] , prompting the suggestion that all patients with iTTP should be treated up-front with rituximab in conjunction with TPE; however, this suggestion is still being debated 162 . To prevent overtreatment, it is important to consider that at least 50% of patients can recover from an acute iTTP episode with standard TPE alone or with the addition of corticosteroids 4, 19, 124, 148, 163 .
Splenectomy
Splenectomy was performed as a last resort in patients with TTP for many years with mixed results (reviewed in REF. 164) before the introduction of TPE and in the absence of any effective treatment. The understanding of the pathophysiology of iTTP now provides a rationale to treat patients who relapse or are refractory to TPE and/or rituximab treatment by splenectomy 76, 88, 165 . A study reporting the long-term (median: ~9 years) follow-up of 33 patients with recurring or refractory TTP who underwent splenectomy showed that it led to remission in all but one patient, and the 10-year relapse-free survival in the whole cohort was 70% 166 .
Comparing the efficacy of splenectomy with that of rituximab in the treatment of refractory or recurrent iTTP would require a difficult-to-perform randomized controlled trial. Evidence suggests that splenic B cells that produce anti-ADAMTS13 autoantibodies might escape anti-CD20 therapy in some patients 88 . If splenectomy is considered in a patient with relapsing or refractory iTTP, a laparoscopic surgical procedure should be preferred, and the patient should at least be partially stabilized by TPE 166 .
Other drugs Immunomodulatory drugs. These drugs aim to suppress the production of anti-ADAMTS13 autoantibodies in patients with refractory iTTP who had suboptimal responses to other treatments and are often prescribed as a last resort. Vincristine was used mainly in the pre-rituximab era. Although a review of 56 studies showed that 73% of patients receiving vincristine achieved stable remission 167 , it is likely that many (or most) treatment failures of vincristine were not reported, as the confidence of haematologists in this drug to treat iTTP waned over the years and it is now rarely used. Cyclosporine A has been reported to be effective 168 , with clinical responses correlating with improved ADAMTS13 activity and the suppression of anti-ADAMTS13 autoantibody production 169 . However, a recent randomized clinical trial showed no statistically significant difference in the exacerbation rate between patients treated with cyclosporine A or corticosteroids as adjunctive therapy 170 .
Platelet count and ADAMTS13 activity can recover with cyclophosphamide 171 , but because of its severe adverse effects (that is, bone marrow suppression, infectious complications, decreased fertility and a longterm risk of malignancy), this drug is justified only in rituximab-resistant, refractory patients.
Bortezomib, a proteasome inhibitor used to treat multiple myeloma and antibody-mediated rejection of transplanted solid organs, was effectively used to eliminate anti-ADAMTS13 autoantibody-producing plasma cells that are resistant to the usual immunosuppressive therapies in some patients [172] [173] [174] [175] . N-acetylcysteine. N-acetylcysteine (NAC) is approved for the treatment of acetaminophen toxicity or for bronchoalveolar obstruction, and has been shown to inhibit platelet adherence to endothelial cell-anchored vWF multimers (possibly soluble ones too) 176, 177 and to reduce the size of soluble high-molecular-weight vWF multimers in vitro 176 . The anti-thrombotic effect of NAC might predominantly result from the reduction of the 1278-1458 disulfide bond in the vWF A1 domain that is important for vWF binding to platelet glycoprotein Ibα [176] [177] [178] .
Recent studies in animal models of TTP demonstrated that NAC alone was effective in preventing the development of severe acute TTP signs (in mice), but could not reverse them once established (in mice and baboons) 179 . NAC has not been approved for use in TTP or other TMAs. As of 2017, three papers have described the successful 'off-label' use of NAC (in conjunction with continued TPE) in five patients with refractory TTP 178, 180, 181 , whereas NAC treatment failed in three other patients with refractory TMA 174, [182] [183] [184] .
Quality of life Relapse
Each acute TTP episode exposes the patient to a risk of morbidity and mortality. The prevention of relapses is, therefore, a rationale to treat patients with TTP in clinical remission. In cTTP, relapses may become frequent after the first episode and some patients depend on regular plasma infusions every 2-3 weeks to maintain normal platelet count and to avoid clinical TTP manifestations and long-term morbidity 52 .
In iTTP, relapses occur in as many as 40% of patients who survive the first disease episode within 7-10 years of follow-up 19 . In a series of patients with other forms of TMA besides iTTP, relapses affected almost exclusively individuals with iTTP 19,163 , and recurrent episodes were usually associated with severe acquired ADAMTS13 deficiency 90 . Although a few patients with iTTP might achieve and remain in remission despite persisting severely reduced ADAMTS13 activity 19,90,185 , the majority of patients recover ADAMTS13 activity upon remission. It has been suggested that the decrease in ADAMTS13 activity during remission is a strong risk factor for ensuing disease recurrence 186, 187 . Thus, routine measurements of ADAMTS13 activity and auto antibody titres may help in long-term disease management. In a small prospective study, lower ADAMTS13 activity and younger age were predictive of relapse within 3 months, whereas inhibitory auto antibody titres were not correlated 186 . However, another study suggested that high titres of inhib itory anti-ADAMTS13 IgG antibodies at presentation were associ ated with undetectable ADAMTS13 activity during remission and predicted relapses within 18 months 90 . Recently, Page et al. 188 reported on patients with iTTP from the Oklahoma TTP-HUS registry who had prolonged periods of severe ADAMTS13 deficiency without experiencing acute TTP episodes. In some patients, ADAMTS13 activity recovered spontaneously to normal levels and none of these patients relapsed, whereas up to 60% of patients with a severe ADAMTS13 deficiency in remission experienced at least one TTP relapse. The French TMA Reference Center Network recently reported their results on 30 patients with iTTP who were preemptively treated with rituximab during remission 189 . Rituximab reduced the incidence of relapse with minimal adverse effects; however, in about one-third of patients, further cycles of rituximab were required to maintain detectable levels of ADAMTS13 activity, and 16% of patients required other immunomodulatory drugs and/or splenectomy 189 . Nevertheless, pre-emptive rituximab treatment should be considered for patients in remission who experience frequent and/or severe episodes of iTTP 189 .
Comorbidities and sequelae
Many patients with iTTP experience reduced healthrelated quality of life 190 . Detailed neurocognitive investigation of 24 patients who were followed up for a median of 4 years after an acute episode of iTTP revealed that their concentration, information processing, rapid language generation and memory performance were significantly worse than standardized adjusted data 191 . These deficits were interpreted as the result of diffuse subcortical microvascular disease, although they did not correlate with the presence or severity of neurological symptoms during the acute TTP episode or episodes.
Survivors (n = 57) of a first acute episode of iTTP who were enrolled in the Oklahoma TTP-HUS registry were followed up for a median of 8 years 28 . The point prevalences of arterial hypertension (40%) and major depression (19%) in these patients were greater than expected from the matched general population (23% and 6%, respectively). Furthermore, the mortality of the cohort was substantially higher than that of the US and local Oklahoma populations, respectively, and this increase was suggested to be related to the higher number of comorbidities in patients with iTTP than in the general population 28 .
However, whether cognitive alterations, depression, arterial hypertension, other comorbidities and increased mortality are specific features of individuals who survive an acute episode of iTTP or are equally present in patients surviving other acute severe diseases remains to be investigated. In addition, a possibly ongoing autoimmune response, evidenced by the presence of circulating ADAMTS13 immune complexes even years after an acute iTTP episode 96 , as well as other autoimmune disorders (particularly connective tissue diseases) that might develop over time 28, 192 could have a role. The creation of comprehensive prospective registries, regular follow-up and long-term observation will be instrumental in finally improving the outlook for patients with iTTP and cTTP.
Outlook
Although the clinicians' awareness of TTP as well as our understanding of its underlying pathophysiology have substantially increased, diagnosing and treating TTP remain a challenge.
New drugs vWF A1 domain targeted therapy.
Two small molecules that specifically block the vWF A1 domain, thereby preventing platelet binding, have been tested in patients with iTTP. ARC1779, an oligonucleotide aptamer, was not further explored after early termination of the phase II trial owing to difficulties in patient recruitment and financing, but the study still provided valuable proof of principle for the vWF A1 domain-blocking approach 193, 194 . The second compound, caplacizumab (formerly known as ALX-0081), is a nanobody (that is, a single-domain antibody) derived from single-chain antibodies that naturally occur in Camelidae. It was assessed in the TITAN trial, a multicentre, randomized, placebo-controlled phase II study in patients with iTTP. Time to platelet recovery was significantly shorter and biomarkers reflecting ischaemic organ damage normalized more rapidly in patients who received caplacizumab in addition to standard-of-care treatment 195 . The incidence of exacerbations was also reduced, but because caplacizumab does not target the ongoing autoimmune response, the relapse rate shortly after withdrawal of the study drug per protocol (30 days after the last TPE session) was increased. Many relapsing patients had persistent severe ADAMTS13 deficiency, indicating that blocking the vWF A1 domain prevented platelet clumping in the microvasculature. Bleeding-related adverse events were more common in the caplacizumab arm (53% versus 38% in the placebo group), but most were mild and did not require an intervention, and the frequency of serious bleeding events was similar in both treatment arms 195 . Caplacizumab is currently under further evaluation in the HERCULES trial, a multicentre phase III study 196 .
Recombinant ADAMTS13. Recombinant ADAMTS13 is expected to benefit patients with cTTP who depend on plasma therapy. Inaugural in vitro experiments on plasma from patients with cTTP as well as iTTP 197, 198 have demonstrated that the addition of recombinant ADAMTS13 effectively restored vWF-cleaving activity.
In the presence of functional ADAMTS13 inhibitory autoantibodies, the required amount of recombinant ADAMTS13 was dependent on the inhibitor titre 198 . Efficacy and feasibility were also proved in various animal models of cTTP and iTTP [199] [200] [201] . A phase I trial using recombinant ADAMTS13 (BAX930) in patients with cTTP has been completed 202 , and first results are expected in late 2017.
'Second trigger' hypothesis
Some patients with cTTP do not develop acute TTP for many years, and, similarly, some patients with iTTP may remain in remission while having undetectable levels of ADAMTS13 activity for prolonged periods of time 19,23,188 . These findings led to the hypothesis that a second hit or a trigger is needed to induce overt TTP 203 . Patients often report infections in the week or weeks preceding an acute TTP episode. In vitro, increased levels of cytokines (for example, tumour necrosis factor and IL-8) that are released during infection and inflammation stimulate human endothelial cells to release vWF from Weibel-Palade bodies 204 , whereas human neutrophil peptides, which are released from activated and degranulated neutrophils, inhibit proteolytic cleavage of vWF by ADAMTS13 in vitro 205 . Another possible trigger are nucleosomes, which are detected at presentation in the majority of patients with an acute TTP episode 206 . These nucleosomes are derived, at least in part, from neutrophil extracellular traps, which are networks made of nuclear DNA, histones, granular and cytoplasmic proteins that are released by neutrophils in response to infections. Neutrophil extracellular traps, circulating extracellular DNA and histones have been shown to be prothrombotic and may promote organ damage 206 .
Disease modifiers
Given the overlapping clinical features between TTP and HUS, pre-eclampsia, HELLP syndrome and (catastrophic) antiphospholipid syndrome, the genes and proteins involved in these conditions might have a role as disease modifiers and modulators of the severity of TTP.
Other proteases as a possible rescue system. Other proteases might help to regulate the size of vWF multimers, as vWF proteolysis has been observed in the acute phase of TTP when ADAMTS13 activity is undetectable 207 . In vitro studies have shown that various enzymes, including various leukocyte proteases 142 , plasmin 208 , granzyme B 209 and thrombin 210 , can cleave vWF, and injection of streptokinase (to generate plasmin) attenuated TTP symptoms in an Adamts13 −/− mouse model of TTP 211 . Although it is tempting to assign a back-up role to some of these enzymes in the absence of ADAMTS13, this hypothesis has not been proved. Furthermore, plasmin, thrombin and factor Xa (although all in supra-physiological concentrations) have been reported to cleave ADAMTS13, thereby reducing its activity 212 . Interestingly, a case of acquired TTP has been described in which ADAMTS13 activity was severely deficient as ADAMTS13 was proteolysed during the acute phase of the disease, which was linked to an acquired, transient deficiency of α2-antiplasmin activity 213 .
β2-glycoprotein I. β2-glycoprotein I interacts with the vWF A1 domain in its glycoprotein Ib-binding conformation, that is, platelet-binding conformation, and thereby abrogates platelet binding to vWF. Anti-β2-glycoprotein I antibodies are found in patients with antiphospholipid syndrome and are thought to contribute to the prothrombotic state in this condition. Du et al. 214 found reduced levels of β2-glycoprotein I in patients with iTTP who present with acute TTP episodes and in remission, which directly correlated with ADAMTS13 activity. In addition, this study showed that adhesion of β2-glycoprotein I to erythrocytes and platelets was enhanced in the presence of ultra-large vWF multimers or a hyperactive vWF A1 domain, which, at least in part, explains the reduced levels of β2-glycoprotein I during acute iTTP episodes.
